Immunocastration — using vaccination to temporarily suppress reproductive hormone production rather than surgical castration — offers a significant welfare improvement for male livestock that would otherwise undergo surgical castration. Widely used in pigs under the brand name Improvac, immunocastration is also being developed for cattle and other species.
Improvac (for pigs) uses two injections of a GnRH (gonadotrophin-releasing hormone) analogue conjugated to a carrier protein. The immune response to the carrier protein creates antibodies that also neutralize GnRH, temporarily suppressing testosterone production and testicular function. Effects are reversible — testicular function resumes after the immune response wanes. The second injection, given 4-6 weeks before slaughter, establishes effective suppression for the slaughter period.
Immunocastration eliminates: acute surgical pain, post-surgical wound pain (24-72 hours), infection risk at surgical site, potential for chronic neurological pain at amputation site, and the stress of handling and restraint for surgery. The injections cause brief injection-site discomfort — a minor welfare cost compared to surgical castration. From a welfare perspective, immunocastration is clearly preferable to surgical castration when it achieves the same production objectives.
Consumer acceptance of "vaccinated" pork has been a market barrier in some countries, particularly Germany, where labeling requirements create stigma. Education campaigns emphasizing that immunocastration is a welfare improvement over surgical castration, and that the product is indistinguishable from conventionally castrated pork at consumption, are needed to overcome misperceptions.
Improvac is licensed in over 60 countries. It is used extensively in Australia, South America, and parts of Europe. EU approval enables use across member states, though uptake varies significantly by country.
Part of the Animal Welfare Hub — 2407+ pages of evidence-based animal welfare information.